http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101540838-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2012-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101540838-B1 |
| titleOfInvention | MET inhibitors for enhancing radiotherapy efficacy |
| abstract | A Met inhibitor and / or a nucleotide sequence encoding it, wherein the Met inhibitor is selected for use in the treatment of cancer patients to reduce and / or eliminate the patient's resistance to radiotherapy are: i) an anti-Met monoclonal (Ii) a genetically engineered antibody comprising complementarity determining regions (CDRs) of an anti-Met monoclonal antibody, and (iii) a complementarity determining region (CDRs) of an anti-Met monoclonal antibody. (ii), or combinations thereof. |
| priorityDate | 2011-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 465.